C Number:

Study Gender:

PWG Approval Date

PA10R: Statistical Analysis of Non-Neoplastic Lesions with Litter Incidence

Test Compound: Diisobutyl Phthalate CAS Number: 84-69-5 Date Report Requested: 01/09/2020 Time Report Requested: 07:23:03 Lab: RTI

R10997

Both

See web page for date of PWG Approval

PA10R: Statistical Analysis of Non-Neoplastic Lesions with Litter Incidence

Test Compound: Diisobutyl Phthalate

CAS Number: 84-69-5

	F0 Male				
	Treatment Groups (ppm)				
	0	1000	5000	10000	
Disposition Summary					
Animals Initially In Study	23	23	23	23	
Early Deaths					
Scheduled Deaths					
Scheduled sacrifice, terminal (SD 139 - 141)	23	23	23	23	
Number of Animals Examined	23	10	6	23	
ALIMENTARY SYSTEM					
LIVER	(23)	(0)	(0)	(23)	
BILE DUCT; HYPERPLASIA				1 (4.3%)	
INFLAMMATION; FOCAL				3 (13%)	
HEPATOCYTE; NECROSIS				1 (4.3%)	
CARDIOVASCULAR SYSTEM					
None					
ENDOCRINE SYSTEM					
ADRENAL GLAND	(23)	(0)	(0)	(23)	
CORTEX; VACUOLATION; DIFFUSE				1 (4.3%)	
CORTEX; VACUOLATION; FOCAL	2 (8.7%)				
PITUITARY GLAND	(22)	(0)	(0)	(22)	
PARS DISTALIS; CYST				1 (4.5%)	
RATHKE'S CLEFT; DILATION				1 (4.5%)	
GENERAL BODY SYSTEM					
FAT	(0)	(0)	(0)	(1)	
INFLAMMATION, CHRONIC				1 (100%)	

PA10R: Statistical Analysis of Non-Neoplastic Lesions with Litter Incidence

Test Compound: Diisobutyl Phthalate

CAS Number: 84-69-5

	F0 Male			
	Treatment Groups (ppm)			
	0	1000	5000	10000
GENITAL SYSTEM				
DORSAL PROSTATE	(23)	(0)	(0)	(23)
INFLAMMATION, CHRONIC	1 (4.3%)			
EPIDIDYMIS	(23)	(0)	(0)	(23)
DUCT; EXFOLIATED GERM CELL	3 (13%)			2 (8.7%)
MINERAL				1 (4.3%)
NECROSIS				1 (4.3%)
SPERM GRANULOMA	2 (8.7%)			
PREPUTIAL GLAND	(10)	(10)	(4)	(9)
INFLAMMATION, CHRONIC	7 (70%)	6 (60%)	2 (50%)	7 (77.8%)
BILATERAL; INFLAMMATION, SUPPURATIVE	1 (10%)	2 (20%)	2 (50%)	2 (22.2%)
INFLAMMATION, SUPPURATIVE	2 (20%)	1 (10%)		
TESTIS	(23)	(0)	(0)	(23)
GERMINAL EPITHELIUM; DEGENERATION	4 (17.4%)			5 (21.7%)
SEMINIFEROUS TUBULE; MINERAL				1 (4.3%)
SEMINIFEROUS TUBULE; NECROSIS				1 (4.3%)
VENTRAL PROSTATE	(23)	(0)	(0)	(23)
INFILTRATION CELLULAR; LYMPHOCYTE	3 (13%)			
INFLAMMATION, CHRONIC	2 (8.7%)			2 (8.7%)
INFLAMMATION, CHRONIC-ACTIVE	1 (4.3%)			1 (4.3%)
HEMATOLYMPHOID SYSTEM				
THYMUS	(23)	(0)	(0)	(23)
HYPERPLASIA; EPITHELIAL	2 (8.7%)			1 (4.3%)
NTEGUMENTARY SYSTEM				
SKIN	(0)	(0)	(1)	(1)
ULCERATION			1 (100%)	1 (100%)

Study Number: R10997 Test Type: RACB Route: Dosing in Feed Species/Strain: Rat/Sprague-Dawley	PA10R: Statistical Analysis of Non-Neoplastic Lesions with Litter Incidence Test Compound: Diisobutyl Phthalate CAS Number: 84-69-5		Date Report Requested: 01/09/202 Time Report Requested: 07:23:03 Lab: RTI		
	F0 Male				
		Treatment Groups (ppm)			
	0	1000	5000	10000	
MUSCULOSKELETAL SYSTEM None					
NERVOUS SYSTEM None					
RESPIRATORY SYSTEM None					
SPECIAL SENSES SYSTEM None					
URINARY SYSTEM KIDNEY CHRONIC PROGRESSIVE NEPHROPATHY DYSPLASIA	(23) 21 (91.3%) 1 (4.3%)	(0)	(0)	(23) 22 (95.7%)	
INFARCT INFLAMMATION; INTERSTITIAL PAPILLA; MINERAL	2 (8.7%)			1 (4.3%) 1 (4.3%)	
PELVIS; MINERAL				1 (4.3%)	

PA10R: Statistical Analysis of Non-Neoplastic Lesions with Litter Incidence

Test Compound: Diisobutyl Phthalate

CAS Number: 84-69-5

	F0 Female				
	Treatment Groups (ppm)				
	0	1000	5000	10000	
Disposition Summary					
Animals Initially In Study	23	23	23	23	
Early Deaths					
Euthanized, moribund	2	2	2	1	
Unscheduled Sacrifice			1		
Scheduled Deaths					
Scheduled sacrifice, terminal (SD 176 - 177)	21	21	20	22	
Number of Animals Examined	23	3	4	23	
ALIMENTARY SYSTEM					
LIVER	(23)	(0)	(1)	(23)	
INFLAMMATION; FOCAL	1 (4.3%)		1 (100%)	1 (4.3%)	
CARDIOVASCULAR SYSTEM					
None					
ENDOCRINE SYSTEM					
ADRENAL GLAND	(23)	(0)	(0)	(23)	
NECROSIS				1 (4.3%)	
CORTEX; VACUOLATION; FOCAL	1 (4.3%)			1 (4.3%)	
THYROID GLAND	(23)	(0)	(0)	(23)	
C-CELL; HYPERPLASIA	1 (4.3%)			1 (4.3%)	
GENERAL BODY SYSTEM					
FAT	(1)	(0)	(0)	(0)	
NECROSIS	1 (100%)				

PA10R: Statistical Analysis of Non-Neoplastic Lesions with Litter Incidence

Test Compound: Diisobutyl Phthalate

CAS Number: 84-69-5

	F0 Female				
	Treatment Groups (ppm)				
	0	1000	5000	10000	
GENITAL SYSTEM					
CLITORAL GLAND	(1)	(0)	(0)	(1)	
INFLAMMATION, SUPPURATIVE	1 (100%)			1 (100%)	
OVARY	(23)	(0)	(0)	(23)	
CORPUS LUTEUM; BILATERAL; CYST				2 (8.7%)	
CORPUS LUTEUM; CYST				1 (4.3%)	
CYST; EPITHELIAL				1 (4.3%)	
CYST	3 (13%)			2 (8.7%)	
UTERUS	(21)	(0)	(0)	(23)	
DILATION	1 (4.8%)			1 (4.3%)	
ENDOMETRIUM; HYPERPLASIA; CYSTIC	2 (9.5%)				
ENDOMETRIUM; METAPLASIA; SQUAMOUS	1 (4.8%)			1 (4.3%)	
POLYP; STROMAL				2 (8.7%)	
VAGINA	(21)	(0)	(0)	(23)	
MUCIFICATION				1 (4.3%)	
HEMATOLYMPHOID SYSTEM					
SPLEEN	(0)	(0)	(2)	(1)	
EXTRAMEDULLARY HEMATOPOIESIS			2 (100%)	1 (100%)	
THYMUS	(23)	(0)	(0)	(23)	
HYPERPLASIA; EPITHELIAL	3 (13%)				

PA10R: Statistical Analysis of Non-Neoplastic Lesions with Litter Incidence

Test Compound: Diisobutyl Phthalate

CAS Number: 84-69-5

	F0 Female			
		Treatment G	Groups (ppm)	
	0	1000	5000	10000
INTEGUMENTARY SYSTEM				
MAMMARY GLAND	(2)	(3)	(2)	(0)
INFLAMMATION, ACUTE		1 (33.3%)		
INFLAMMATION, CHRONIC-ACTIVE		1 (33.3%)		
SKIN	(1)	(0)	(0)	(0)
HAIR FOLLICLE; INFLAMMATION, CHRONIC	1 (100%)			
SKIN, ABDOMINAL	(0)	(0)	(0)	(1)
ULCERATION				1 (100%)
MUSCULOSKELETAL SYSTEM				
None				
NERVOUS SYSTEM				
None				
RESPIRATORY SYSTEM				
None				
SPECIAL SENSES SYSTEM				
None				
URINARY SYSTEM				
KIDNEY	(23)	(0)	(1)	(23)
CHRONIC PROGRESSIVE NEPHROPATHY	19 (82.6%)		1 (100%)	17 (73.9%)
MEDULLA; BILATERAL; CYST				1 (4.3%)
MEDULLA; CYST				4 (17.4%)
CORTICOMEDULLARY JUNCTION; MINERAL	9 (39.1%)		1 (100%)	6 (26.1%)
NEPHROBLASTEMATOSIS	1 (4.3%)			

Test Compound: Diisobutyl Phthalate

CAS Number: 84-69-5

	F1 Male : F1c NonParent Males			
		Treatment	Groups (ppm)	
	0	1000	5000	10000
Disposition Summary				
Animals Initially In Study	45	31	39	40
Early Deaths				
Euthanized, moribund				1
Scheduled Deaths				
Scheduled sacrifice, terminal (PND 90 - 92)	45	31	39	39
Number of Animals Examined	45	31	39	40
Total number litters	17	13	17	16
ALIMENTARY SYSTEM				
LIVER	(45)	(1)	(2)	(40)
INFLAMMATION; CHRONIC		1 (100%) [1]		1 (2.5%) [1]
INFLAMMATION; FOCAL	32 (71.1%) [15]			31 (77.5%) [15]
HEPATOCYTE; NECROSIS			1 (50%) [1]	
POLYARTERITIS NODOSA			1 (50%) [1]	
CARDIOVASCULAR SYSTEM				
None				
ENDOCRINE SYSTEM				
ADRENAL GLAND	(45)	(0)	(1)	(40)
CORTEX; HYPERPLASIA			1 (100%) [1]	
POLYARTERITIS NODOSA			1 (100%) [1]	
CORTEX; VACUOLATION; DIFFUSE				2 (5%) [2]
PITUITARY GLAND	(45)	(31)	(39)	(40)
PARS DISTALIS; CYST; MULTIPLE			1 (2.6%) [1]	
PARS DISTALIS; CYST	3 (6.7%) [3]	1 (3.2%) [1]	2 (5.1%) [2]	1 (2.5%) [1]
PARS INTERMEDIA; CYST				1 (2.5%) [1]
PARS DISTALIS; HYPERTROPHY				3 (7.5%) [2]

Study Number: R10997 Test Type: RACB Route: Dosing in Feed Species/Strain: Rat/Sprague-Dawley	-	ysis of Non-Neoplastic L st Compound: Diisobutyl F CAS Number: 84-69-		=	quested: 01/09/2020 equested: 07:23:03
	F1 M	ale : F1c NonParent Mal	es		
	-		Treatment Groups	(ppm)	
		0	1000	5000	10000

Test Compound: Diisobutyl Phthalate

CAS Number: 84-69-5

	Treatment Groups (ppm)			
	0	1000	5000	10000
ENITAL SYSTEM				
COWPERS GLAND	(44)	(31)	(39)	(39)
HYPOPLASIA				1 (2.6%) [1]
DORSAL PROSTATE	(45)	(31)	(39)	(38)
INFLAMMATION, CHRONIC	1 (2.2%) [1]			
EPIDIDYMIS	(45)	(31)	(39)	(40)
DUCT; ATROPHY			1 (2.6%) [1]	3 (7.5%) [2]
DUCT; EXFOLIATED GERM CELL	3 (6.7%) [2] *		5 (12.8%) [4]	8 (20%) [7]
HYPOSPERMIA	1 (2.2%) [1]		1 (2.6%) [1]	4 (10%) [3]
IMMATURE				1 (2.5%) [1]
SPERM GRANULOMA			1 (2.6%) [1]	
LEVATOR ANI PLUS BULBOCAVERNOSUS MUSCLE	(45)	(0)	(2)	(39)
HYPOPLASIA				1 (2.6%) [1]
PREPUTIAL GLAND	(2)	(0)	(1)	(1)
DUCT; DILATION				1 (100%) [1]
INFLAMMATION, CHRONIC	1 (50%) [1]		1 (100%) [1]	
TESTIS	(45)	(31)	(39)	(39)
GERMINAL EPITHELIUM; ATROPHY				1 (2.6%) [1]
GERMINAL EPITHELIUM; DEGENERATION	3 (6.7%) [2] **	1 (3.2%) [1]	8 (20.5%) [6]	10 (25.6%) [8] '
SEMINIFEROUS TUBULE; DYSGENESIS	1 (2.2%) [1]		2 (5.1%) [1]	2 (5.1%) [2]
EDEMA				2 (5.1%) [1]
INTERSTITIAL CELL; HYPERPLASIA; DIFFUSE				2 (5.1%) [1]
INTERSTITIAL CELL; HYPERPLASIA; FOCAL				2 (5.1%) [2]
IMMATURE				1 (2.6%) [1]
VENTRAL PROSTATE	(45)	(31)	(39)	(40)
IMMATURE				1 (2.5%) [1]
INFILTRATION CELLULAR; LYMPHOCYTE	16 (35.6%) [11]	12 (38.7%) [10]	6 (15.4%) [5]	17 (42.5%) [9]
BILATERAL; INFLAMMATION, CHRONIC	14 (31.1%) [8]	5 (16.1%) [4]	6 (15.4%) [5]	13 (32.5%) [7]

CAS Number: 84-69-5

Date Report Requested: 01/09/2020 Time Report Requested: 07:23:03 Lab: RTI

	Treatment Groups (ppm)			
	0	1000	5000	10000
INFLAMMATION, CHRONIC	2 (4.4%) [2]	3 (9.7%) [3]	9 (23.1%) [7]	3 (7.5%) [3]
HEMATOLYMPHOID SYSTEM				
SPLEEN	(45)	(0)	(1)	(40)
FOLLICLE; ATROPHY; LYMPHOID				1 (2.5%) [1]
EXTRAMEDULLARY HEMATOPOIESIS			1 (100%) [1]	
THYMUS	(45)	(0)	(0)	(40)
HYPERPLASIA; EPITHELIAL	1 (2.2%) [1]			1 (2.5%) [1]
NECROSIS; LYMPHOCYTIC				1 (2.5%) [1]
INTEGUMENTARY SYSTEM				
DIGIT	(0)	(0)	(0)	(1)
HYPOPLASIA				1 (100%) [1
MUSCULOSKELETAL SYSTEM				
None				
NERVOUS SYSTEM				
None				
RESPIRATORY SYSTEM				
None				

None

CAS Number: 84-69-5

	Treatment Groups (ppm)			
	0	1000	5000	10000
IRINARY SYSTEM				
KIDNEY	(45)	(3)	(3)	(40)
CHRONIC PROGRESSIVE NEPHROPATHY	41 (91.1%) [17]		1 (33.3%) [1]	37 (92.5%) [15]
MEDULLA; BILATERAL; CYST	1 (2.2%) [1]			
MEDULLA; CYST				5 (12.5%) [4]
PELVIS; DILATION	3 (6.7%) [2]	3 (100%) [3]	3 (100%) [3]	2 (5%) [2]
INFARCT	1 (2.2%) [1]			
PAPILLA; MINERAL			1 (33.3%) [1]	3 (7.5%) [2]
NEPHROBLASTEMATOSIS				1 (2.5%) [1]
POLYARTERITIS NODOSA			1 (33.3%) [1]	

CAS Number: 84-69-5

Disposition Summary Animals Initially In Study Early Deaths Scheduled Deaths Scheduled sacrifice, terminal (PND 90 - 92) Number of Animals Examined Total number litters	0 28 28 28 28 15	1000 32 32 5 4	5000 40 40 3	10000 32 32 32 32
Animals Initially In Study Early Deaths Scheduled Deaths Scheduled sacrifice, terminal (PND 90 - 92) Number of Animals Examined Total number litters	28 28	32 5	40 3	32
Early Deaths Scheduled Deaths Scheduled sacrifice, terminal (PND 90 - 92) Number of Animals Examined Total number litters	28 28	32 5	40 3	32
Scheduled Deaths Scheduled sacrifice, terminal (PND 90 - 92) Number of Animals Examined Total number litters	28	5	3	
Scheduled sacrifice, terminal (PND 90 - 92) Number of Animals Examined Total number litters LIMENTARY SYSTEM	28	5	3	
Number of Animals Examined Total number litters	28	5	3	
Total number litters				32
LIMENTARY SYSTEM	15	4		
			3	13
LIVER				
	(28)	(0)	(1)	(32)
HEPATODIAPHRAGMATIC NODULE			1 (100%) [1]	
BILE DUCT; HYPERPLASIA				1 (3.1%) [1]
INFLAMMATION; FOCAL	2 (7.1%) [2]			4 (12.5%) [4]
MINERAL; FOCAL				1 (3.1%) [1]
MESENTERY	(2)	(1)	(0)	(0)
FAT; NECROSIS		1 (100%) [1]		
ARDIOVASCULAR SYSTEM				
None				
NDOCRINE SYSTEM				
ADRENAL GLAND	(28)	(0)	(1)	(32)
POLYARTERITIS NODOSA			1 (100%) [1]	
PITUITARY GLAND	(28)	(0)	(0)	(32)
PARS DISTALIS; CYST	2 (7.1%) [2]			

CAS Number: 84-69-5

	Treatment Groups (ppm)				
	0	1000	5000	10000	
GENITAL SYSTEM					
OVARY	(28)	(0)	(0)	(32)	
CORPUS LUTEUM; CYST	1 (3.6%) [1]				
INTERSTITIAL CELL; HYPERPLASIA	· /			1 (3.1%) [1]	
UTERUS	(28)	(1)	(0)	(32)	
CERVIX; CYST; SQUAMOUS	1 (3.6%) [1]		· · /		
CYST		1 (100%) [1]			
DILATION	2 (7.1%) [2]			2 (6.3%) [2]	
ENDOMETRIUM; HYPERPLASIA; CYSTIC				2 (6.3%) [2]	
IEMATOLYMPHOID SYSTEM					
SPLEEN	(28)	(0)	(1)	(32)	
EXTRAMEDULLARY HEMATOPOIESIS	(20)	(0)	1 (100%) [1]	(32)	
THYMUS	(28)	(0)	(0)	(32)	
HYPERPLASIA; EPITHELIAL	1 (3.6%) [1]	(0)	(0)	(32) 1 (3.1%) [1]	
	1 (3.0%) [1]			1 (3.1%)[1]	
NTEGUMENTARY SYSTEM					
DIGIT	(0)	(1)	(0)	(1)	
DEVELOPMENTAL MALFORMATION		1 (100%) [1]		1 (100%) [1]	
MAMMARY GLAND	(28)	(0)	(0)	(32)	
ACINUS; HYPERPLASIA	3 (10.7%) [3]			5 (15.6%) [4]	
NUSCULOSKELETAL SYSTEM					
None					
IERVOUS SYSTEM					
None					
RESPIRATORY SYSTEM					
None					

Study Number: R10997 Test Type: RACB Route: Dosing in Feed Species/Strain: Rat/Sprague-Dawley	PA10R: Statistical Analysis of Non-Neoplastic Test Compound: Diisobutyl CAS Number: 84-69-	Phthalate	=	Requested: 01/09/2020 t Requested: 07:23:03
	F1 Female : F1c NonParent Fe	male		
		Treatment Groups	s (ppm)	
	0	1000	5000	10000
SPECIAL SENSES SYSTEM None				
URINARY SYSTEM				
KIDNEY	(28)	(1)	(1)	(32)
CHRONIC PROGRESSIVE NEPHROPATHY	11 (39.3%) [8]			19 (59.4%) [10]
PELVIS; DILATION			1 (100%) [1]	
INFARCT	1 (3.6%) [1]			
CORTICOMEDULLARY JUNCTION; MINERAL PAPILLA; MINERAL	19 (67.9%) [12]			15 (46.9%) [7] 2 (6.3%) [1]

Test Compound: Diisobutyl Phthalate

CAS Number: 84-69-5

Date Report Requested: 01/09/2020 Time Report Requested: 07:23:03 Lab: RTI

	Treatment Groups (ppm)				
	0	1000	5000	10000	
Disposition Summary					
Animals Initially In Study	40	40	40	40	
Early Deaths					
Unscheduled Sacrifice			3		
Scheduled Deaths					
Scheduled sacrifice, terminal (PND 213 - 223)	40	40	37	40	
Number of Animals Examined	40	40	40	40	
Total number litters	21	20	19	18	
ALIMENTARY SYSTEM					
LIVER	(40)	(0)	(3)	(40)	
BILE DUCT; HYPERPLASIA				1 (2.5%) [1]	
INFLAMMATION; FOCAL	5 (12.5%) [5]			5 (12.5%) [4]	
HEPATOCYTE; NECROSIS				1 (2.5%) [1]	

None

PA10R: Statistical Analysis of Non-Neoplastic Lesions with Litter Incidence

Test Compound: Diisobutyl Phthalate

CAS Number: 84-69-5

Date Report Requested: 01/09/2020 Time Report Requested: 07:23:03 Lab: RTI

	Treatment Groups (ppm)			
	0	1000	5000	10000
ENDOCRINE SYSTEM				
ADRENAL GLAND	(40)	(0)	(3)	(40)
CORTEX; HYPERTROPHY; FOCAL	2 (5%) [2]			
CORTEX; VACUOLATION; DIFFUSE	2 (5%) [2]			3 (7.5%) [3]
CORTEX; VACUOLATION; FOCAL	3 (7.5%) [3]			1 (2.5%) [1]
PITUITARY GLAND	(40)	(40)	(40)	(40)
PARS DISTALIS; CYST	4 (10%) [4]	2 (5%) [2]	2 (5%) [2]	
PARS INTERMEDIA; CYST	1 (2.5%) [1]			
PARS DISTALIS; HYPERPLASIA				1 (2.5%) [1]
PARS DISTALIS; HYPERTROPHY	0 *		1 (2.5%) [1]	4 (10%) [3]
THYROID GLAND	(40)	(0)	(3)	(40)
INFILTRATION; MONONUCLEAR CELL	1 (2.5%) [1]			

None

Test Compound: Diisobutyl Phthalate

CAS Number: 84-69-5

F1 Male : F1c Parental Males				
		Treatment 0	Groups (ppm)	
	0	1000	5000	10000
GENITAL SYSTEM				
COWPERS GLAND	(40)	(40)	(40)	(40)
HYPOPLASIA				1 (2.5%) [1]
DORSAL PROSTATE	(40)	(0)	(3)	(40)
INFLAMMATION, ACUTE			1 (33.3%) [1]	1 (2.5%) [1]
EPIDIDYMIS	(40)	(40)	(40)	(39)
DUCT; ATROPHY	0 **		2 (5%) [2]	5 (12.8%) [5]
DUCT; EXFOLIATED GERM CELL	2 (5%) [2] *	1 (2.5%) [1]	3 (7.5%) [3]	6 (15.4%) [5]
HYPOPLASIA	0 *		1 (2.5%) [1]	3 (7.7%) [3]
HYPOSPERMIA	0 **		3 (7.5%) [3]	8 (20.5%) [6] *
PREPUTIAL GLAND	(2)	(1)	(2)	(8)
DUCT; DILATION				2 (25%) [2]
BILATERAL; INFLAMMATION, CHRONIC	1 (50%) [1]			
INFLAMMATION, CHRONIC	1 (50%) [1]			
BILATERAL; INFLAMMATION, SUPPURATIVE			1 (50%) [1]	2 (25%) [2]
INFLAMMATION, SUPPURATIVE		1 (100%) [1]	1 (50%) [1]	4 (50%) [3]
SEMINAL VESICLE	(40)	(0)	(3)	(40)
INFLAMMATION; ACUTE				1 (2.5%) [1]
TESTIS	(40)	(40)	(40)	(39)
GERMINAL EPITHELIUM; ATROPHY	0 **			5 (12.8%) [5]
GERMINAL EPITHELIUM; DEGENERATION	2 (5%) [2] **	3 (7.5%) [3]	7 (17.5%) [6]	13 (33.3%) [10] *
SEMINIFEROUS TUBULE; DYSGENESIS		1 (2.5%) [1]	1 (2.5%) [1]	1 (2.6%) [1]
EDEMA	0 *		1 (2.5%) [1]	4 (10.3%) [4]
INTERSTITIAL CELL; HYPERPLASIA; DIFFUSE	0 *		1 (2.5%) [1]	4 (10.3%) [4]
INTERSTITIAL CELL; HYPERPLASIA; FOCAL	0 *			4 (10.3%) [4]
HYPOPLASIA			1 (2.5%) [1]	2 (5.1%) [2]
MINERAL			1 (2.5%) [1]	
VENTRAL PROSTATE	(40)	(40)	(40)	(40)

CAS Number: 84-69-5

Date Report Requested: 01/09/2020 Time Report Requested: 07:23:03 Lab: RTI

	Treatment Groups (ppm)				
	0	1000	5000	10000	
INFILTRATION CELLULAR; LYMPHOCYTE	5 (12.5%) [5]			8 (20%) [7]	
INFLAMMATION, CHRONIC	1 (2.5%) [1]	5 (12.5%) [5]	4 (10%) [4]	3 (7.5%) [3]	
HEMATOLYMPHOID SYSTEM					
LYMPH NODE	(0)	(0)	(0)	(1)	
HYPERPLASIA; PLASMA CELL				1 (100%) [1]	
THYMUS	(40)	(0)	(3)	(39)	
ATROPHY	1 (2.5%) [1]				
HYPERPLASIA; EPITHELIAL	7 (17.5%) [6]			3 (7.7%) [3]	
INTEGUMENTARY SYSTEM					
SKIN	(0)	(0)	(0)	(1)	
INFLAMMATION, SUPPURATIVE				1 (100%) [1]	
MUSCULOSKELETAL SYSTEM					
None					
NERVOUS SYSTEM					
None					
RESPIRATORY SYSTEM					
None					

None

CAS Number: 84-69-5

	F1 Male : F1c Parental Males				
	Treatment Groups (ppm)				
	0	1000	5000	10000	
URINARY SYSTEM					
KIDNEY	(40)	(1)	(3)	(40)	
PELVIS; CALCULUS	6 (15%) [5]				
CHRONIC PROGRESSIVE NEPHROPATHY	39 (97.5%) [21]	1 (100%) [1]	3 (100%) [3]	40 (100%) [18]	
MEDULLA; CYST	1 (2.5%) [1]				
PELVIS; DILATION	2 (5%) [2]	1 (100%) [1]		3 (7.5%) [3]	
CORTICOMEDULLARY JUNCTION; MINERAL				1 (2.5%) [1]	
PAPILLA; MINERAL	1 (2.5%) [1]			5 (12.5%) [4]	
PELVIS; MINERAL	1 (2.5%) [1]				

Test Compound: Diisobutyl Phthalate

CAS Number: 84-69-5

		Treatment G	iroups (ppm)	
	0	1000	5000	10000
Disposition Summary				
Animals Initially In Study	40	40	40	40
Early Deaths				
Euthanized, moribund	1		4	
Found Dead	1		1	
Scheduled Deaths				
Scheduled sacrifice, terminal (LD 21, PND 232 - 237)	38	40	35	40
Number of Animals Examined	40	7	9	40
Total number litters	20	7	9	18
ALIMENTARY SYSTEM				
LIVER	(40)	(2)	(6)	(40)
HEPATODIAPHRAGMATIC NODULE		1 (50%) [1]	1 (16.7%) [1]	
BILE DUCT; HYPERPLASIA				1 (2.5%) [1]
INFLAMMATION; FOCAL	2 (5%) [2]		1 (16.7%) [1]	
HEPATOCYTE; NECROSIS		1 (50%) [1]	1 (16.7%) [1]	
MESENTERY	(0)	(1)	(1)	(0)
FAT; NECROSIS		1 (100%) [1]		
PERIARTERITIS			1 (100%) [1]	
CARDIOVASCULAR SYSTEM				
HEART	(0)	(0)	(1)	(0)
CARDIOMYOPATHY			1 (100%) [1]	
POLYARTERITIS NODOSA			1 (100%) [1]	

Test Compound: Diisobutyl Phthalate

CAS Number: 84-69-5

ENDOCRINE SYSTEM ADRENAL GLAND (40) (0) (5) (40) CORTEX; HEMORRHAGE 1 (20%) [1] 1 1 1 CORTEX; HYPERPLASIA 1 (20%) [1] 1 1 1 1 PITUITARY GLAND (40) (0) (5) (40) PARS DISTALIS; CYST 3 (7.5%) [2] 2 (5%) [2] 2 (5%) [2] THYROID GLAND (40) (0) (5) (40)		Treatment Groups (ppm)			
ADRENAL GLAND (40) (0) (5) (40) CORTEX; HEMORRHAGE 1 (20%) [1] 1 (20%) [1] 1 (20%) [1] CORTEX; HYPERPLASIA 1 (20%) [1] 1 (20%) [1] 1 (20%) [2] PITUITARY GLAND (40) (0) (5) (40) PARS DISTALIS; CYST 3 (7.5%) [2] 2 (5%) [2] 2 (5%) [2] THYROID GLAND (40) (0) (5) (40) FOLLICLE; CYST 1 (2.5%) [1] 1 (2.5%) [1] 1 (2.5%) [1]		0	1000	5000	10000
CORTEX; HEMORRHAGE 1 (20%) [1] CORTEX; HYPERPLASIA 1 (20%) [1] PITUITARY GLAND (40) (0) (5) (40) PARS DISTALIS; CYST 3 (7.5%) [2] 2 (5%) [2] 2 (5%) [2] THYROID GLAND (40) (0) (5) (40) FOLLICLE; CYST 1 (2.5%) [1] 1 (2.5%) [1]	ENDOCRINE SYSTEM				
CORTEX; HYPERPLASIA 1 (20%) [1] PITUITARY GLAND (40) (0) (5) (40) PARS DISTALIS; CYST 3 (7.5%) [2] 2 (5%) [2] 2 (5%) [2] THYROID GLAND (40) (0) (5) (40) FOLLICLE; CYST 1 (2.5%) [1] 1 (2.5%) [1]	ADRENAL GLAND	(40)	(0)	(5)	(40)
PITUITARY GLAND (40) (0) (5) (40) PARS DISTALIS; CYST 3 (7.5%) [2] 2 (5%) [2] THYROID GLAND (40) (0) (5) (40) FOLLICLE; CYST 1 (2.5%) [1] 1 (2.5%) [1]	CORTEX; HEMORRHAGE			1 (20%) [1]	
PARS DISTALIS; CYST 3 (7.5%) [2] 2 (5%) [2] THYROID GLAND (40) (0) (5) FOLLICLE; CYST 1 (2.5%) [1]	CORTEX; HYPERPLASIA			1 (20%) [1]	
THYROID GLAND (40) (0) (5) (40) FOLLICLE; CYST 1 (2.5%) [1	PITUITARY GLAND	(40)	(0)	(5)	(40)
FOLLICLE; CYST 1 (2.5%) [1	PARS DISTALIS; CYST	3 (7.5%) [2]			2 (5%) [2]
	THYROID GLAND	(40)	(0)	(5)	(40)
C-CELL; HYPERPLASIA 1 (2.5%) [1]	FOLLICLE; CYST				1 (2.5%) [1]
	C-CELL; HYPERPLASIA	1 (2.5%) [1]			
	None				

CAS Number: 84-69-5

		Treatment G	roups (ppm)	
	0	1000	5000	10000
ENITAL SYSTEM				
CERVIX	(40)	(0)	(5)	(40)
INFLAMMATION; ACUTE			1 (20%) [1]	
POLYARTERITIS NODOSA			1 (20%) [1]	
CLITORAL GLAND	(3)	(1)	(1)	(0)
DUCT; DILATION	1 (33.3%) [1]			
INFLAMMATION, SUPPURATIVE		1 (100%) [1]	1 (100%) [1]	
OVARY	(40)	(0)	(5)	(40)
CORPUS LUTEUM; BILATERAL; CYST	2 (5%) [2]			1 (2.5%) [1]
CORPUS LUTEUM; CYST	4 (10%) [4]			
CYST	1 (2.5%) [1]			1 (2.5%) [1]
POLYARTERITIS NODOSA			1 (20%) [1]	
UTERUS	(39)	(1)	(5)	(40)
CERVIX; CYST; SQUAMOUS	1 (2.6%) [1]			
ENDOMETRIUM; CYST	2 (5.1%) [1]			
SUBSEROSA; CYST		1 (100%) [1]		
ENDOMETRIUM; DILATION; GLANDULAR, CYSTIC				2 (5%) [1]
DILATION	1 (2.6%) [1]			
INFLAMMATION; ACUTE	_		2 (40%) [2]	
ENDOMETRIUM; METAPLASIA; SQUAMOUS	1 (2.6%) [1]			
POLYARTERITIS NODOSA			1 (20%) [1]	
POLYP; STROMAL	1 (2.6%) [1]			
VAGINA	(40)	(0)	(5)	(40)
CYST; SQUAMOUS	1 (2.5%) [1]			
INFLAMMATION; ACUTE			1 (20%) [1]	1 (2.5%) [1]
MUCIFICATION			1 (20%) [1]	
POLYARTERITIS NODOSA			1 (20%) [1]	

Test Compound: Diisobutyl Phthalate

CAS Number: 84-69-5

		Treatment	Groups (ppm)	
	0	1000	5000	10000
HEMATOLYMPHOID SYSTEM				
LYMPH NODE, AXILLARY	(1)	(0)	(1)	(0)
HYPERPLASIA; LYMPHOCYTE			1 (100%) [1]	
HYPERPLASIA; PLASMA CELL	1 (100%) [1]			
LYMPH NODE, MANDIBULAR	(0)	(0)	(1)	(0)
HYPERPLASIA; LYMPHOID			1 (100%) [1]	
SPLEEN	(40)	(0)	(5)	(40)
EXTRAMEDULLARY HEMATOPOIESIS	1 (2.5%) [1]		5 (100%) [5]	
THYMUS	(39)	(0)	(4)	(40)
ATROPHY	10 (25.6%) [8]			12 (30%) [11
CYST	1 (2.6%) [1]			
HYPERPLASIA; EPITHELIAL	3 (7.7%) [3]			4 (10%) [4]
NTEGUMENTARY SYSTEM				
MAMMARY GLAND	(38)	(2)	(6)	(40)
INFLAMMATION; ACUTE			1 (16.7%) [1]	
SKIN	(1)	(0)	(0)	(0)
INFLAMMATION, SUPPURATIVE	1 (100%) [1]			
SKIN, SUBCUTANEOUS TISSUE	(0)	(0)	(1)	(0)
INFLAMMATION, SUPPURATIVE			1 (100%) [1]	
MUSCULOSKELETAL SYSTEM				
None				
NERVOUS SYSTEM				
None				
RESPIRATORY SYSTEM				
None				

Study Number: R10997 Test Type: RACB Route: Dosing in Feed Species/Strain: Rat/Sprague-Dawley	PA10R: Statistical Analysis of Non-Neoplastic L Test Compound: Diisobutyl F CAS Number: 84-69-5	Phthalate		Requested: 01/09/2020 Requested: 07:23:03
	F1 Female : F1c Parental Fema	ales		
		Treatment Group	os (ppm)	
	0	1000	5000	10000
SPECIAL SENSES SYSTEM None				
URINARY SYSTEM		· · · · · · · · · · · · · · · · · · ·		
KIDNEY	(40)	(0)	(6)	(40)
CHRONIC PROGRESSIVE NEPHROPATHY	30 (75%) [17]		6 (100%) [6]	34 (85%) [17]
MEDULLA; CYST	1 (2.5%) [1]			
PAPILLA; DILATION; TUBULAR				1 (2.5%) [1]
PELVIS; DILATION			1 (16.7%) [1]	
CORTICOMEDULLARY JUNCTION; MINERAL	33 (82.5%) [18]		3 (50%) [3]	13 (32.5%) [11] **
PAPILLA; MINERAL	2 (5%) [2]			3 (7.5%) [3]
NEPHROBLASTEMATOSIS				1 (2.5%) [1]
POLYARTERITIS NODOSA			1 (16.7%) [1]	

Date Report Requested: 01/09/2020 Time Report Requested: 07:23:03 Lab: RTI

LEGEND

Number of animals examined for each tissue shown in parentheses. If none of the animals examined have the specific lesion then there is a blank for that dose group for that specific lesion. The exception to this is if statistical significance is found for a lesion and the control group has no animals with the lesion then a 0 is included for the control group on the table for that lesion.

Number of animals with observation reported with percent incidence in parentheses

Number of litters with observations shown in square brackets for F1 and F2 animals. F1 litter incidence based on the number of F0 dams; F2 litter incidence based on number of F1 dams.

Trend significance is reported only for those organs that were fully examined in the control group plus two or more other dose groups. For organs that were fully examined in just the control and one other dose group, only the pairwise significance is reported.

All trend and pairwise p-values are reported as one-sided.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

Non-pregnant females from the F0 and F1 generations are included in the analysis.

Statistical analysis for the F0 animals was performed by Cochran-Armitage test with poly-3 adjustment for both trend and pairwise tests.

Statistical analysis for the F1 Non-parental and F2 animals was performed by Cochran-Armitage test with a Rao-Scott modification for the random effect due to litter.

Statistical analysis for the F1 Parental animals was performed by Cochran-Armitage test with a poly-3 adjustment for age and a Rao-Scott modification for the random effect due to litter.

* Statistically significant at P <= 0.05

** Statistically significant at P <= 0.01

** END OF REPORT **